Lack of evidence for increased operative morbidity after hepatectomy with perioperative use of bevacizumab: A matched case-control study Academic Article uri icon

Overview

MeSH Major

  • Angiogenesis Inhibitors
  • Antibodies, Monoclonal
  • Colorectal Neoplasms
  • Hepatectomy
  • Liver Neoplasms

abstract

  • Clinical experience thus far does not indicate a statistically significantly increased risk of perioperative complications with the incorporation of bev into pre- and/or postoperative treatment paradigms. Given the long half-life of bev and the potential for anti-VEGF therapy to impede wound healing and/or liver regeneration, we continue to favor a window of 6 to 8 weeks between bev administration and surgery.

publication date

  • February 2007

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1245/s10434-006-9074-0

PubMed ID

  • 17103075

Additional Document Info

start page

  • 759

end page

  • 65

volume

  • 14

number

  • 2